Measuring Sarcopenic Obesity in People with COPD
Studies how often sarcopenic obesity occurs in adults with COPD, a lung disease.
Plain-language title generated from the registry record
Registry title: Prevalence of Sarcopenic Obesity in COPD
Key facts
- Where
- Roma, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 100 years old?
Source: NCT06822504, who can take part
Where in Italy
- IRCCS San RaffaeleRoma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele Roma
- Trial code
- NCT06822504
- Record updated
- 12 February 2025
- Original description
The goal of this observational study is to the purpose is to apply of ESPEN/EASO criteria for the diagnosis of sarcopenic obesity and calculation of OS prevalence in a sample of COPD patients.Read full original descriptionShow less
ESPEN-EASO Sarcopenic Obesity (OS) Diagnostic Criteria Application in a COPD Cohort and OS Correlation to Diaphragmatic Thickness and Mobility for Determination of Tailored Pulmonary Rehabilitation Program: an Observational Study
The goal of this observational study is to the purpose is to apply of ESPEN/EASO criteria for the diagnosis of sarcopenic obesity and calculation of OS prevalence in a sample of COPD patients.
In addition, this study want to evaluate the impact of sarcopenic obesity on the respiratory function of COPD patients and the degree of severity of respiratory disease, assessed by spirometric examination; diaphragm thickness and excursion, by ultrasonographic study; performance, assessed by six-minute walk test (6-MWT); quality of life and degree of dyspnea (mMRC, Barthel dyspnea, S. George Respiratory Questionnaire); compliance and outcomes at the end of the respiratory rehabilitation course. Comparison with normal-weight patients with and without sarcopenia will help to better understand the clinical impact of sarcopenic obesity in this category of patients.
Inclusion: Patients aged > 40 years of either sex; BMI >18.5; COPD diagnosis according to the GOLD [2021 Global initiative for chronic obstructive lung disease] classification in the stable stage; Signing of informed consent after receiving all information about the study.
Exclusion: uncontrolled hypertension (systolic blood pressure > 160 mmHg, diastolic > 100 mmHg); intercurrent infectious diseases, including HIV diagnosis; Patients diagnosed with malignancy in progress or in remission for less than 5 years; patients diagnosed with severe neurological, rheumatologic, or musculoskeletal diseases; patients with a history of thoracic surgery; presence of severe aortic stenosis, uncontrolled atrial/ventricular arrhythmia, recent cardiac ischemic event; cognitive impairment conditions that prevent full understanding of the study protocol (mental retardation, dementia, etc.) and/or adequate test performance compliance; failure to sign informed consent; any other serious medical condition that may interfere with data interpretation and safety or that may make the respiratory rehabilitation course difficult, limited, or uncomfortable; COPD not stabilized at the time of enrollment; BMI < 18.5; presence of tracheostomy; hypotension (systolic blood pressure <100 mm Hg); Significant comorbidities that limit exercise tolerance.